Companies Dominating the HER2 Testing Market
- Agilent Technologies, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Thermo Fisher Scientific
- Roche
- Empire Genomics Inc.
- Abnova Corporation
- Eli Lilly and Company
- Oxford Gene Technology IP Limited
- Genetech
- Genemed Technologies Inc.
- PERKINELMER Inc.
Browse Key Market Insights with Data Illustration:
In the News
- Roche announced that the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody has received approval from the U.S. FDA. When a patient has low HER2 expression, this antibody can be used to identify them and assist assess whether Enhertu is a good targeted treatment choice for them.
- Eli Lilly and Company declared that the expanded use of Verzenio (abemaciclib) in conjunction with endocrine therapy (ET) has received approval from the U.S. FDA. Adjuvant treatment for adult patients with hormone receptor-positive (HR+), HER2-negative, node-positive early breast cancer (EBC) who are at high risk of recurrence is now permitted with this approval.
